



US005872124A

**United States Patent** [19]**Koprowski et al.**[11] **Patent Number:** **5,872,124**[45] **Date of Patent:** **Feb. 16, 1999**

[54] **TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM USING URIC ACID AS A SCAVENGER OF PEROXYNITRITE**

[75] Inventors: **Hilary Koprowski**, Wynnewood, Pa.;  
**Douglas Craig Hooper**, Medford, N.J.;  
**John L. Farber**, St. Davids, Pa.

[73] Assignee: **Thomas Jefferson University**,  
Philadelphia, Pa.

[21] Appl. No.: **690,110**

[22] Filed: **Jul. 31, 1996**

[51] **Int. Cl.<sup>6</sup>** ..... **A01N 43/90**

[52] **U.S. Cl.** ..... **514/261**; 514/183; 514/256;  
514/262; 514/263

[58] **Field of Search** ..... 514/12, 183, 179,  
514/740, 261

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

5,449,688 9/1995 Wahl et al. .... 514/546  
5,455,279 10/1995 Lipton .  
5,464,857 11/1995 Maeda et al. .... 514/398

**FOREIGN PATENT DOCUMENTS**

9511231 4/1995 WIPO .  
9614842 5/1996 WIPO .

**OTHER PUBLICATIONS**

Cross AH, et al, (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. *J Clin Invest* 93:2684-2690.

Dawson VL, et al, (1996) Nitric oxide neurotoxicity. *J Chem.Neuroanat.* 10:179-190.

Heales SJ, et al, (1994) Trolox protects mitochondrial complex IV from nitric oxide-mediated damage in astrocytes. *Brain Res.* 668:243-245.

Iadecola C, et al, (1995) Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. *Am.J Physiol.* 268:R286-R292.

Kooy NW, et al, (1994) Agonist-induced peroxynitrite production from endothelial cells. *Arch.Biochem.Biophys.* 310:352-359.

Maeda H, et al, (1994) Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. *J Leukoc.Biol.* 56:588-592.

Takaaki Akaike et al., Effect of neurotropic virus infection on neuronal and inducible nitric oxide synthase activity in rat brain, *Journal of NeuroVirology* (1995), vol. 32, 118-125.

Omar Bagasra et al., Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis, *Proc. Natl. Acad. Sci. USA* (Dec. 1995) 12041-12045.

D. Craig Hooper et al., Local nitric oxide production in viral and autoimmune diseases of the central nervous system, *Proc. Natl. Acad. Sci. USA* (Jun. 1995) 5312-5316.

Hilary Koprowski et al., In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases, *Proc. Natl. Acad. Sci. USA* (1993) 3024-3027.

Sergei V. Spitsin et al., Characterization and Functional Analysis of the Human Inducible Nitric Oxide Synthase Gene Promoter, *Molecular Medicine* (Mar. 1996) 226-235.

Takaaki Akaike et al., Antagonistic Action of Imidazolinexoxly N-Oxides against Endothelium-Derived Relaxing Factor/NO through a Radical Reaction, *Biochemistry* (1993), vol. 32, 827-832.

Nuran Akgören et al., Importance of nitric oxide for local increases of blood flow in rat cerebellar cortex during electrical stimulation, *Proc. Natl. Acad. Sci. USA* (1994), vol. 91, 5903-5907.

(List continued on next page.)

*Primary Examiner*—Lora M. Green

*Attorney, Agent, or Firm*—Volpe and Koenig, P.C.

[57] **ABSTRACT**

The process of treating a disease of the central nervous system with an agent from one or more of the following three classes of agents: (1) nitric oxide scavengers, (2) peroxynitrite scavengers, and (3) agents that either interfere with the synthesis of iNOS in the cell or the enzymatic activity of iNOS in the cell.

**5 Claims, 14 Drawing Sheets**

